Targeting a cornerstone of radiation resistance: Cancer stem cell

Cancer Letters

Volumn 322, Issue 2, 2012, Pages 139-147

  Moncharmont, Coralie ^a   Levy, Antonin ^b   Gilormini, Marion ^a   Bertrand, Gérald ^a   Chargari, Cyrus ^c   Alphonse, Gersende ^a   Ardail, Dominique ^a   Rodriguez Lafrasse, Claire ^a   Magné, Nicolas ^a  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University of Paris Descartes   (France)

Author keywords

Cancer stem cells; Hypoxia; Radiation therapy; Radioresistance

Indexed keywords

AMUVATINIB; BETA CATENIN; BORTEZOMIB; BUTHIONINE SULFOXIMINE; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CUCURBITACIN; CUCURBITACIN 1; FREE RADICAL; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE REGULATION; DNA REPAIR; DRUG TARGETING; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; HYPOXIA; ION THERAPY; LUNG METASTASIS; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

EID: 84861701350     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.024     Document Type: Review

References (94)

1. Schatton T., Frank N.Y., Frank M.H. Identification and targeting of cancer stem cells. BioEssays 2009, 10:1038-1049.
2. Hill R.P., Milas L. The proportion of stem cells in murine tumours. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16:513-518.
3. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A.R., Sansom O.J., Clevers H. Crypts stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
4. Zhu L., Gibson P., Currle D.S., Tong Y., Richardson R.J., Bayazitov I.T., Poppleton H., Zakharenko S., Ellison D.W., Gilbertson R.J. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 45:603-607.
5. Alcantara Llaguno S., Chen J., Kwon C.H., Jackson E.L., Li Y., Burns D.K., Alvarez-Buylla A., Parada L.F. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
6. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
7. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
8. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108:7950-7955.
9. Pajonk F., Vlashi E., McBride W.H. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010, 28:639-648.
10. Mils L., Hittelman W.N. Cancer stem cells and tumour response to therapy: current problems and future prospects. Semin. Radiat. Oncol. 2009, 19:96-105.
11. Chang J.Y., Zhang X., Vassiliev O., Gillin M., Mohan R., et al. Proton therapy targets cancer stem cells in treatment-resistant non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:S644.
12. Cui X., Oonishi K., Tsujii H., Yasuda T., Matsumoto Y., Frusawa Y., Akashi M., Kamada T., Okayasu R. Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays. Cancer Res. 2011, 71:3676-3687.
13. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
14. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 2006, 98:1777-1785.
15. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/b-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2007, 104:618-623.
16. Parikh S.D., Levina V., Wang T., Gibson M.K., Lokshin A.E. Radioresistance of non-small cell lung cancer stem cells. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:S542-S543.
17. Campos B., Herold-Mende C.C. Insight into the complex regulation of CD133 in glioma. Int. J. Cancer 2011, 128:501-510.
18. Miyabayashi T., Teo J.L., Yamamoto M., McMillan M., Nguyen C., Kahn M. Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc. Natl. Acad. Sci. USA 2007, 104:5668-5673.
19. Pawlik T.M., Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:928-942.
20. Wilson A., Laurenti E., Oser G., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135:1118-1129.
21. Kendziorra E., Ahlborn K., Spitzner M., Rave-Fränk M., Emons G., Gaedcke J., Kramer F., Wolff H.A., Becker H., Beissbarth T., Ebner R., Ghadimi B.M., Pukrop T., Ried T., Grade M. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011, 32:1824-1831.
22. Rich J.N. Cancer stem cells in radiation resistance. Cancer Res. 2007, 67:8980-8984.
23. Yin H., Glass J. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS ONE 2011, 6:e24080.
24. Cao R., Tsukada Y., Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol. Cell 2005, 20:845-854.
25. Facchino S., Abdouh M., Chatoo W., Bernier G. BMI confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J. Neurosci. 2010, 30:10096-10111.
26. Gieni R.S., Ismail I.H., Campbell S., Hendzel M.J. Polycomb group proteins in the DNA damage response: a link between radiation resistance and " stemness" . Cell Cycle 2011, 10:883-894.
27. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
28. Zhivotovsky B., Kroemer G. Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol. 2007, 5:752-762.
29. J. Bensimon, S. Altmeyer-Morel, H. Benjelloun, S. Chevillard, J. Lebeau, CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability, Oncogene, 2012. doi: (Epub ahead of print). http://dx.doi.org/10.1038/onc.2012.31.
30. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., Domingo D., Yahalom J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001, 61:439-444.
31. Abedin M.J., Wang D., McDonnell M.A., Lehmann U., Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ. 2007, 14:500-510.
32. Gewirtz D.A., Hilliker M.L., Wilson E.N. Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells. Radiother. Oncol. 2009, 92:323-328.
33. Zhuang W., Li B., Long L., Chen L., Huang Q., Liang Z.Q. Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res. 2011, 1371:7-15.
34. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4:437-447.
35. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Kinklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson RJ R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
36. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
37. Smith J., Ladi E., Mayer-Proschel M., Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl. Acad. Sci. USA 2000, 97:10032-10037.
38. Tsatmali M., Walcott E.C., Crossin K.L. Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res. 2005, 1040:137-150.
39. Riley R.A. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol. 1994, 65:27-33.
40. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug. Discov. 2009, 8:579-591.
41. Boonstra J., Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337:1-13.
42. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF1 regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
43. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 2008, 8:425-437.
44. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., Shi Q., Cao Y., Lathia J., McLendon R.E., Hjelmeland A.B., Rich J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
45. McCord A.M., Jamal M., Shankavarum U.T., Lang F.F., Camphausen K., Tofilon P.J. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol. Cancer Res. 2009, 7:489-497.
46. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., Keith B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20:557-570.
47. Pietras A., Gisselsson D., Ora I., Noguera R., Beckman S., Navarro S., Pahlman S. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J. Pathol. 2008, 214:482-488.
48. Toole B.P. Hyaluronan-CD44 Interactions in cancer: paradoxes and possibilities. Clin. Cancer Res. 2009, 15:7462-7468.
49. Bissell M.J., Labarge M.A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 2005, 7:17-23.
50. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
51. Gupta P.B., Proia D., Cingoz O., Weremowicz J., Naber S.P., Weinberg R.A., Kuperwasser C. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007, 67:2062-2071.
52. Li Y., Welm B., Podsypanina K., Huang S., Chamorro M., Zhang X., Rowlands T., Egeblad M., Cowin P., Werb Z., Tan L.K., Rosen J.M., Varmus H.E. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA 2003, 100:15853-15858.
53. Chen M.S., Woodward W.A., Behbod F., Peddibhotla S., Alfaro M.P., Buchholz T.A., Rosen J.M. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J. Cell Sci. 2007, 120:468-477.
54. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
55. Theodosiou N.A., Tabin C.J. Wnt signaling during development of the gastrointestinal tract. Dev. Biol. 2003, 15:258-271.
56. Taipale J., Beachy P.A. The hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411:349-354.
57. Hadjihannas M.V., Bruckner M., Jerchow B., Birchmeier W., Dietmaier W., Behrens J. Aberrant Wnt/b-catenin signalling can induce chromosomal instability in colon cancer. Proc. Natl. Acad. Sci. USA 2006, 103:10747-10752.
58. Ayyanan A., Civenni G., Ciarloni L., Morel C., Mueller N., Lefort K., Mandinova A., Raffoul W., Fiche M., Dotto G.P., Brisken C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 2006, 103:3799-3804.
59. Shiras A., Chettiar S.T., Shepal V., Rajendran G., Prasad G.R., Shastry P. Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 2007, 25:1478-1489.
60. Che S.M., Zhang X.Z., Hou L., Song T.B. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest. 2010, 28:679-688.
61. Che S.M., Zhang X.Z., Liu X.L., Chen X., Hou L. The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis. Esophagus 2011, 24:265-273.
62. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
63. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
64. Zhan J.F., Wu L.P., Chen L.H., Yuan Y.W., Xie G.Z., Sun A.M., Liu Y., Chen Z.X. Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation. Cell Oncol. (Dordr) 2011, 34:451-456.
65. Rich J.N., Eyler C.E. Cancer stem cells in brain tumor biology. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:411-420.
66. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., Piccirillo S., Vescovi A.L., DiMeco F., Olivi A., Eberhart C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
67. Clement V., Sanchez P., de Tribolet N., Radovanovic I., Ruiz I., Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 2007, 17:165-172.
68. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.M., Eberhart C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66:7445-7452.
69. Lee J., Son M.J., Woolard K., Donin N.M., Li A., Cheng C.H., Kotliarova S., Kotliarov Y., Walling J., Ahn S., Kim M., Totonchy M., Cusack T., Ene C., Ma H., Su Q., Zenklusen J.C., Zhang W., Maric D., Fine F.A. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13:69-80.
70. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., DiMeco F., Vescovi A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
71. Soeda A., Inagaki A., Oka N., Ikegame Y., Aoki H., Yoshimura S., Nakashima S., Kunisada T., Iwama T. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J. Biol. Chem. 2008, 283:10958-10966.
72. Wang J., Wakeman T.P., Lathia J.D., Hjelmeland A.B., Wang X.F., White R.R., Rich J.N., Sullenger B.A. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28:17-28.
73. Stephanou A., Brar B.K., Knight R.A., Latchman D.S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 2000, 7:329-330.
74. Rahaman S.O., Harbor P.C., Chernova O., Barnett G.H., Vogelbaum M.A., Haque S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
75. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26:2435-2444.
76. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589.
77. Chen Y.W., Chen K.H., Huang P.I., Chen Y.C., Chiou G.Y., Lo W.L., Tseng L.M., Hsu H.S., Chang K.W., Chiou S.H. Cucurbitacin 1 suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma -derived CD44(+)ALDH1(+) cells. Mol. Cancer Ther. 2010, 11:2879-2892.
78. Hsu H.S., Huang P.I., Chang Y.L., Tzao C., Chen Y.W., Shih H.C., Hung S.C., Chen Y.C., Tseng L.M., Chiou S.H. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011, 117:2970-2985.
79. Nguyen N.P., Almeida F.S., Chi A., Nguyen L.M., Cohen D., Karisson U., Vinh-Hung V. Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat. Rev. 2010, 36:485-491.
80. Günther H.S., Schmidt N.O., Phillips H.S., Kemming D., Kharbanda S., Soriano R., Modrusan Z., Meissner H., Westphal M., Lamszus K. Gli lastoma-derived stem cell-enriched cultures from distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27:2897-2899.
81. Ellsworth R., Welsh J., Mahadevan D., Bearrs D., Hsieh D., Fjerstad K., Marsella M., Sanan A., Badrudojja M., Slea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, Mp470 in glioblastoma multiforme stem cells. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:S714-S715.
82. Sun Y., Zheng S., Speirs C., Kopsombut P., Zhao Z., Lu B. Gene profiling of cancer stem cells-like cells reveals IGF-1R and IGFBP3 pathway as a promising therapeutic target for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:S131.
83. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
84. Cufí S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Joven J., Menendez J.A. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010, 15:4461-4468.
85. Jung J.W., Park S.B., Lee S.J., Seo M.S., Trosko J.E., Kang K.S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE 2011, 6:e28068.
86. Kahana S., Finniss S., Cazacu S., Xiang C., Lee H.K., Brodie S., Goldstein R.S., Roitman V., Slavin S., Mikkelsen T., Brodie C. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. Cell. Signal. 2011, 23:1348-1357.
87. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., Caparros E., Buteau J., Brown K., Perkins S.L., Bhagat G., Agarwal A.M., Basso G., Castillo M., Nagase S., Cordon-Cardo C., Parsons R., Zúñiga-Pflücker J.C., Dominguez M., Ferrando A.A. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 2007, 13:1203-1210.
88. Abounader R., Reznik T., Colantuoni C., Martinez-Murillo F., Rosen E.M., Laterra J. Regulation of c-Met-dependent gene expression by PTEN. Oncogene 2004, 23:9173-9182.
89. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-2567.
90. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8:545-554.
91. Supiot S., Lisbona A., Paris F., Azria D., Fenoglietto P. " Dose-painting" : myth or reality?. Cancer Radiother. 2010, 14:554-562.
92. Ling C.C., Humm J., Larson S., Amols H., Fuks Z., Leibel S., Koutcher J.A. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47:551-560.
93. Piao L.S., Hur W., Kim T.K., Hong S.W., Kim S.W., Choi J.E., Sung P.S., Song M.J., Lee B.C., Hwang D., Yoon S.K. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012, 315:129-137.
94. Zhang Q., Shi S., Yen Y., Brown J., Ta J.Q., Le A.D. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010, 289:151-160.